MediPoint: Peripheral Vascular Stents for the Lower Extremity – US Analysis and Market Forecasts

Share it with your friends Like

Thanks! Share it with your friends!


London (PRWEB) September 19, 2013


Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. Through GlobalDatas analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

The peripheral vascular stent market is a large and dynamic one that allows stent manufacturers to develop different types of vascular stent platforms for different types of arteries in the lower extremity. As PAD presents enormous global public health and socioeconomic issues, it is pertinent to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current peripheral vascular stent market for the lower extremity in the US, and evaluates the adoption and opportunities for this technology.


An overview of PAD, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
Annualized US PVS market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
Investigation of current and future market competition for PVS
Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
Competitor assessment including device approval analysis and device sales forecasts.
Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
Analysis of unmet needs within the market and opportunities for future players.
Technology trends evaluation to assess strength of pipeline.
An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
Company profiles including business description, financial overview and SWOT analysis.
Coverage of key market players.
Strategic assessment of the PVS sector through market impact analysis, future market scenario and company analysis.
Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy:

Understand the trends shaping and driving the US PVS Market.
Realize device preferences of physicians who have performed the tests already.
Access market sizing, forecasts and quantified growth opportunities in the US PVS Market through 2018.
Quantify candidate patient populations to better design product pricing & launch plans.
Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
Perform benchmarking analysis of growth opportunities against currently marketed products.
Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
Take a comprehensive look at the markets device pipeline and identify promising, paradigm-shifting products.
Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
Whats the next big thing in US PVS market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 7

1.1 List of Tables 14

1.2 List of Figures 22

2 Introduction 24

2.1 Catalyst 25

2.2 Related Reports 25

3 Peripheral Artery Disease 26

3.1 Overview 26

3.2 Anatomy and Physiology 26

3.2.1 Peripheral Arteries of the Lower Extremity 27

3.3 Pathophysiology 28

3.4 Clinical Presentation 30

3.4.1 Symptoms of Peripheral Artery Disease 30

3.4.2 Risk Factors 32

3.4.3 Disease Classification 32

3.4.4 Diagnosis 33

3.5 Clinical Outcomes 34

3.5.1 Treatment Paradigm 34

3.5.2 Treatment Guidelines 35

3.5.3 Treatment Modalities 39

3.5.4 Endovascular Management of PAD 54

3.6 Epidemiology 57

3.6.1 Peripheral Artery Disease 57

3.7 Economic Impact 59

3.7.1 United States 60

3.8 Treatment Costs 61

4 Unmet Needs 63

4.1 Need for Better Clinical Outcomes in Specific Lesions 63

4.1.1 Chronic Total Occlusions 63

4.1.2 Long Lesions 63

4.1.3 Heavily-Calcified and Uncrossable Lesions 64

4.1.4 Bifurcation Lesions 64

4.2 Need to Improve Medical Therapy 64

4.3 Comparative Studies on Exercise Therapy 65

4.4 Addressing Complications of Lower-Extremity Bypass Surgery 65

4.5 Eliminating Mechanisms of Failure with Balloon Angioplasty 66

4.6 Need for Better Revascularization of the Femoropopliteal Artery 66

4.7 Difficulty in Treating the Infrapopliteal Artery 67

4.8 Lack of Clinical Data 68

4.9 Limited Designs of Low-Profile Devices 69

4.10 Addressing Challenges of Peripheral Stenting 69

4.10.1 Risk of Post-Procedural Complications 69

4.10.2 In-Stent Restenosis 71

4.10.3 Stent Fracture 71

4.10.4 Long-Term Vessel Patency 72

4.10.5 Stent Material 72

4.10.6 Stent Deployment and Deliverability 73

4.10.7 Dual Anti-Platelet Therapy 74

4.10.8 Imaging 74

5 Industry Overview 75

5.1 Procedure Trends 75

5.1.1 Factors Contributing to Rise of Peripheral Interventions 75

5.1.2 United States 75

5.2 Market Access 78

5.2.1 United States 78

5.3 Reimbursement Trends 82

5.3.1 United States 82

5.4 Regulatory Issues/Recalls 84

5.4.1 Regulatory Issues 84

5.4.2 Recalls 84

5.5 Mergers and Acquisitions 85

5.5.1 Abbott Laboratories 85

5.5.2 Atrium Medical Corporation 86

5.5.3 Boston Scientific Corporation 86

5.5.4 Cordis Corporation (Johnson & Johnson) 87

5.5.5 Covidien 87

5.5.6 CR Bard 87

5.5.7 Medtronic 88

5.5.8 Nexeon Stent 88

5.5.9 Terumo Corporation 89

6 Competitive Assessment 90

6.1 Overview 90

6.1.1 Peripheral Vascular Stent Market 90

6.2 Products 93

6.2.1 Bare Metal Stents 93

6.2.2 Drug-Eluting Stents 167

6.2.3 Covered Stents 173

6.2.4 Bioabsorbable Stents 183

7 Pipeline Products 186

7.1 Overview 186

7.2 Pipeline by Phase of Development 187

7.3 Pipeline Product Profiles Peripheral Artery Disease 189

7.3.1 Citation Stent 189

7.3.2 MR-Enhanced Stents 190

7.3.3 ArtiStent 191

7.3.4 Hybrid Dynamic Stent 191

7.3.5 Nipro Corporation Peripheral Stent 191

7.3.6 Yukon 191

7.3.7 iCAST 193

7.3.8 Peritoneal-Lined Stents 194

7.3.9 LifeJacket Stent Graft 195

7.3.10 Esprit Bioabsorbable Vascular Scaffold (BVS) 196

7.3.11 Magic Explorer Stent 197

7.3.12 Stanza 198&#

Find More Cardiovascular Exercise Press Releases


Comments are disabled for this post.